Non Small Cell Lung Cancer News and Research

RSS

Non-Small Cell Lung Cancers are a group of lung cancers that are named for the kinds of cells found in the cancer and how the cells look under a microscope. The three main types of non-small cell lung cancer are squamous cell carcinoma, large cell carcinoma, and adenocarcinoma. Non-small cell lung cancer is the most common kind of lung cancer.

OXiGENE signs definitive agreement to sell Common Stock

OXiGENE, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, today announced that it has entered into a definitive agreement with certain institutional investors to sell 6,578,945 shares of its Common Stock and separate series of warrants to purchase Common Stock in a private placement.

12 Mar 2010

Peregrine Pharmaceuticals' third-quarter fiscal 2010 total revenues up 45%

Peregrine Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing innovative monoclonal antibodies for the treatment of cancer and serious viral infections, today announced financial results for the third quarter of fiscal year (FY) 2010 ended January 31, 2010. The company also provided an update on its clinical programs and corporate developments.

From Thermo Fisher Scientific Inc. 11 Mar 2010

Idera Pharmaceuticals announces net income of $3.9M for fourth-quarter 2009

Idera Pharmaceuticals, Inc. today reported financial results for the fourth quarter and full year ended December 31, 2009.

10 Mar 2010

Abbott enters into agreement with GSK to develop molecular diagnostic test for skin cancer treatment

Abbott announced today that it has entered into an agreement with GlaxoSmithKline (GSK) to develop a molecular diagnostic test intended for use as an aid in selecting patients who may benefit from a skin cancer treatment in development by GSK.

4 Mar 2010

Study: Salvage targeted therapy can be suitable for elderly patients with NSCLC

Research published in the March issue of the Journal of Thoracic Oncology sought to determine whether differences existed in tolerance and efficacy between patients age 70 and over and younger patients with non-small cell lung cancer (NSCLC) receiving salvage targeted therapy with epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) or chemotherapy.

4 Mar 2010

SCLL signs agreement to provide research and assay services in support of Agennix's talactoferrin program

Stem Cell Innovations announced today that the Company has signed a Master Services Agreement to provide research and assay services in support of Agennix's talactoferrin program. The assay utilizes SCLL's C3A human liver cell line.

3 Mar 2010

Geron highlights telomerase inhibitor's activity against cancer stem cells at AACR Special Conference

Geron Corporation today announced several presentations at the American Association for Cancer Research Special Conference on The Role of Telomeres and Telomerase in Cancer Research held in Fort Worth, TX between February 27th and March 1st.

3 Mar 2010

ArQule reports net loss of $36,136,000 for 2009

ArQule, Inc. today announced its financial results for the year and for the fourth quarter ended December 31, 2009.

2 Mar 2010

New treatment guidelines demonstrate that best care does not always cost more

Arizona Oncology is proud to be a part of the larger network that just completed a recently conducted study by US Oncology and Aetna that finds evidence-based care for patients with non-small cell lung cancer (NSCLC) results in an average cost savings of 35 percent over 12 months while demonstrating equivalent health outcomes.

2 Mar 2010

Peer-reviewed articles elucidate role of clusterin in promoting tumor resistance to cancer treatment

OncoGenex Pharmaceuticals, Inc., announced today that two peer-reviewed articles have been published that further elucidate the biological function of clusterin, its role in promoting tumor resistance to cancer treatment, and the role of an inhibitor of clusterin such as custirsen (OGX-011) that is designed to knock down treatment resistance in the cells and enhance the effectiveness of cancer therapies.

1 Mar 2010

Synta Pharmaceuticals presents preclinical and clinical data of Hsp90 inhibitor STA-9090

Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that Dr. Geoffrey I. Shapiro of Dana-Farber Cancer Institute, presented preclinical and clinical data on STA-9090, a potent second-generation Hsp90 inhibitor, at IASLC (International Association for the Study of Lung Cancer) 10th Annual Targeted Therapies of the Treatment of Lung Cancer Meeting in Santa Monica, CA.

27 Feb 2010

OncoGenex Pharmaceuticals receives CHMP advice on OGX-011 development plan in treatment of mCRPC

OncoGenex Pharmaceuticals announced today that it has received written, scientific advice from the European Medicines Agency (EMA) on the company's development plan for OGX-011 (also known as custirsen) for the treatment of men with metastatic castrate-resistant prostate cancer (mCRPC). The input received from the Committee for Medicinal Products for Human Use (CHMP) at the EMA was in overall agreement with OncoGenex's development plan regarding the proposed preclinical studies and both the study designs and analyses for the Phase III trials.

25 Feb 2010

Novelos Therapeutics' NOV-002 Phase 3 NSCLC trial fails to meet primary survival endpoint

Novelos Therapeutics, Inc., a biopharmaceutical company focused on the development of therapeutics to treat cancer and hepatitis, today announced that the primary endpoint of improvement in overall survival was not met in Novelos’ pivotal Phase 3 trial in advanced non-small cell lung cancer (NSCLC) studying its lead product, NOV-002, in combination with first-line chemotherapy. Detailed trial results are expected to be presented via appropriate scientific venue later this year.

24 Feb 2010

BSD2000 deep hyperthermia combined with chemotherapy improves quality of life in NSCLC patients

BSD Medical Corporation today announced that a study titled “BSD2000 Deep Hyperthermia Combined with Chemotherapy of PT regimen in Patients with Non-small Cell Lung Cancer” has been published in the current issue of The Chinese Journal of Lung Cancer (February 2010;13(2):132–135) by Yang, Zhao, and Wang.

24 Feb 2010

Merrimack Pharmaceuticals commences dosing in MM-121/Tarceva combination Phase 1/2 study for NSCLC

Merrimack Pharmaceuticals, Inc. announced today that the first patient has received an initial dose in a Phase 1/2 clinical study combining MM-121 with Tarceva® (erlotinib) in patients with non-small cell lung cancer (NSCLC). This is the first of multiple trials that Merrimack and sanofi-aventis expect to initiate in 2010 as part of a broad Phase 2 clinical development program for MM-121.

23 Feb 2010

VARI researchers find ways to reverse resistance to sunitinib: Patients with ccRCC show positive response

Van Andel Research Institute researchers have found a way to reverse resistance to sunitinib, a treatment that is currently the first line of defense against clear cell renal cell carcinoma (ccRCC), a deadly form of kidney cancer. Most patients who show a positive response to sunitinib develop a resistance to the drug after one year of treatment.

19 Feb 2010

Antigenics announces fourth-quarter and full-year 2009 financial results

Antigenics Inc. reported today its results for the quarter and year ended December 31, 2009. The company reported net income attributable to common stockholders of $1.7 million, or $0.02 per share, basic and diluted, for the fourth quarter of 2009, compared with net income attributable to common stockholders in the fourth quarter of 2008 of $3.9 million, or $0.06 per share, basic and diluted.

18 Feb 2010

Research assesses the overall efficacy of palliative chest RT in patients with advanced NSCLC

Research published in the February edition of the Journal of Thoracic Oncology sought to assess the overall efficacy of split-course palliative chest radiotherapy (RT) for symptom relief in patients with advanced non-small cell lung cancer. Additionally, researchers investigated the impact the regimen's two-week break has on survival outcomes.

17 Feb 2010

Role of evidence-based pathways in providing high quality, cost effective oncology care

Although health care reform is taking a back seat to the economy on Capitol Hill, discussions continue in the health care industry on how best to lower the cost of care while maintaining or improving patient outcomes.

11 Feb 2010

sanofi-aventis reports 2009 fourth-quarter and full-year net earnings

Commenting on the Group's 2009 performance, sanofi-aventis Chief Executive Officer Christopher A. Viehbacher said, "2009 was the first year of implementation of our new strategy. Major steps have already been achieved in strengthening our growth platforms and reinforcing our R&D pipeline while delivering a double-digit EPS(1) growth".

10 Feb 2010